Distinguished in Non-Small Cell Lung Cancer (NSCLC)

Dr. Sylvia M. Lee

Hematology Oncology | Oncology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sylvia Lee is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Endoscopy. Dr. Lee is currently accepting new patients.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles and participated in 4 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Korean
Mandarin
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug, Biological
Study Drugs: CART-TnMUC1, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Drugs: KITE-439, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug, Other, Biological
Study Drugs: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Therapeutic Tumor Infiltrating Lymphocytes
Study Phase: Phase 2
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Enrollment Status: Terminated
Publish Date: September 13, 2021
Intervention Type: Drug, Biological, Other, Procedure
Study Drugs: Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

43 Total Publications

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Christina S. Baik
Oncology | Hematology Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Christina S. Baik
Oncology | Hematology Oncology

The Association Of University Physicians

325 9th Ave, 
Seattle, WA 
 (3.2 miles away)
206-731-3000
Languages Spoken:
English, Castilian, Hindi, Korean, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Baik is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Baik is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Baik is currently accepting new patients.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Sid H. Devarakonda
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Sid H. Devarakonda
Oncology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
 (2.8 miles away)
206-386-2424
Experience:
16+ years
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sid Devarakonda is an Oncologist in Seattle, Washington. Dr. Devarakonda has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. Dr. Devarakonda is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Rafael Santana
Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Rafael Santana
Oncology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
 (2.8 miles away)
206-386-3751
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rafael Santana is an Oncologist in Seattle, Washington. Dr. Santana is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile